Follow
Elisabeth Perez-Ruiz
Elisabeth Perez-Ruiz
Hospital Regional Universitario de Málaga
Verified email at juntadeandalucia.es
Title
Cited by
Cited by
Year
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
E Perez-Ruiz, L Minute, I Otano, M Alvarez, MC Ochoa, V Belsue, ...
Nature 569 (7756), 428-432, 2019
3552019
Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
N Karachaliou, M Gonzalez-Cao, G Crespo, A Drozdowskyj, E Aldeguer, ...
Therapeutic advances in medical oncology 10, 1758834017749748, 2018
2492018
Antibody‐dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells
MC Ochoa, L Minute, I Rodriguez, S Garasa, E Perez‐Ruiz, S Inogés, ...
Immunology and cell biology 95 (4), 347-355, 2017
2142017
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies
E Pérez-Ruiz, I Melero, J Kopecka, AB Sarmento-Ribeiro, ...
Drug Resistance Updates 53, 100718, 2020
1252020
Bcl-2 inhibition to overcome resistance to chemo-and immunotherapy
M García-Aranda, E Pérez-Ruiz, M Redondo
International journal of molecular sciences 19 (12), 3950, 2018
1242018
Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types
L Paré, T Pascual, E Seguí, C Teixidó, M Gonzalez-Cao, P Galván, ...
Annals of Oncology 29 (10), 2121-2128, 2018
852018
Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer
A Sánchez-Muñoz, C Mendiola, E Pérez-Ruiz, CA Rodríguez-Sánchez, ...
Oncology 79 (1-2), 98-104, 2010
552010
Maintenance treatment in metastatic breast cancer
A Sanchez-Munoz, E Perez-Ruiz, N Ribelles, A Marquez, E Alba
Expert review of anticancer therapy 8 (12), 1907-1912, 2008
532008
Targeted therapy of metastatic breast cancer
A Sánchez-Muñoz, E Pérez-Ruiz, B Jiménez, N Ribelles, A Márquez, ...
Clinical and Translational Oncology 11, 643-650, 2009
512009
The role and prognostic value of apoptosis in colorectal carcinoma
J Alcaide, R Funez, A Rueda, E Perez-Ruiz, T Pereda, I Rodrigo, ...
BMC clinical pathology 13, 1-7, 2013
432013
Clinical and sociodemographic factors that may influence the resilience of women surviving breast cancer: cross-sectional study
M Padilla-Ruiz, C Ruiz-Román, E Pérez-Ruiz, A Rueda, M Redondo, ...
Supportive Care in Cancer 27, 1279-1286, 2019
392019
Tipifarnib in recurrent, metastatic HRAS‐mutant salivary gland cancer
GJ Hanna, JP Guenette, NG Chau, CM Sayehli, C Wilhelm, R Metcalf, ...
Cancer 126 (17), 3972-3981, 2020
372020
Anti-CD137 and PD-1/PD-L1 antibodies en route toward clinical synergy
E Pérez-Ruiz, I Etxeberria, ME Rodriguez-Ruiz, I Melero
Clinical Cancer Research 23 (18), 5326-5328, 2017
372017
Epidemiological characteristics of a Spanish cohort of patients diagnosed with squamous cell carcinoma of head and neck: distribution of risk factors by tumor location
R Seijas-Tamayo, J Fernández-Mateos, JC Adansa Klain, R Mesía, ...
Clinical and Translational Oncology 18, 1114-1122, 2016
322016
Impact of epidermal growth factor receptor expression on disease-free survival and rate of pelvic relapse in patients with advanced cancer of the cervix treated with …
J Pérez-Regadera, A Sánchez-Muñoz, J De-la-Cruz, C Ballestín, D Lora, ...
American Journal of Clinical Oncology 34 (4), 395-400, 2011
322011
Response to paclitaxel in a radiotherapy-induced breast angiosarcoma
E Perez-Ruiz, N Ribelles, A Sanchez-Muñoz, A Roman, A Marquez
Acta Oncologica 48 (7), 1078-1079, 2009
312009
SEOM clinical guideline for the management of cutaneous melanoma (2020)
M Majem, JL Manzano, I Marquez-Rodas, K Mujika, E Muñoz-Couselo, ...
Clinical and Translational Oncology 23, 948-960, 2021
302021
Anti-angiogenic treatment (sunitinib) for disseminated malignant haemangiopericytoma: a case study and review of the literature
M Delgado, E Pérez-Ruiz, J Alcalde, D Perez, R Villatoro, A Rueda
Case Reports in Oncology 4 (1), 55-59, 2011
302011
Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15
MC Ochoa, L Minute, A López, E Pérez-Ruiz, C Gomar, M Vasquez, ...
Oncoimmunology 7 (2), e1393597, 2018
292018
Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells
MC Ochoa, E Perez-Ruiz, L Minute, C Oñate, G Perez, I Rodriguez, ...
Oncoimmunology 8 (7), e1599636, 2019
272019
The system can't perform the operation now. Try again later.
Articles 1–20